Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2b/3 Randomized, Double-blind, Placebo-controlled, Dose-ranging Study To Investigate The Efficacy And Safety Of Pf-06651600 In Adult And Adolescent Alopecia Areata (aa) Subjects With 50% Or Greater Scalp Hair Loss

Next Previous
Trial Profile

A Phase 2b/3 Randomized, Double-blind, Placebo-controlled, Dose-ranging Study To Investigate The Efficacy And Safety Of Pf-06651600 In Adult And Adolescent Alopecia Areata (aa) Subjects With 50% Or Greater Scalp Hair Loss

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 01 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ritlecitinib (Primary)
  • Indications Alopecia areata
  • Focus Registrational; Therapeutic Use
  • Acronyms ALLEGRO-2b/3
  • Sponsors Pfizer

    • Most Recent Events

    • 01 Nov 2023 Results of subgroup analysis (n=105 adolescents ) evaluating the efficacy and safety of ritlecitinib, published in the Pediatric Dermatology
    • 19 Sep 2023 According to a Pfizer media release, the European Commission (EC) has granted marketing authorization for LITFULO (ritlecitinib) to treat adults and adolescents 12 years of age and older with severe alopecia areata.
    • 14 Sep 2023 Results of post hoc analysis from ALLEGRO phase2/3 study assessing identify distinct hair loss profiles at baseline and evaluate whether they affected the efficacy of ritlecitinib published in the Dermatology and Therapy
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top